drugset / Trial / NCT06619860

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860

Phase 2 Recruiting 300 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)

Timeline

Start
2024-10-18
Primary completion
2027-03-25
Completion
2027-04-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pregabalin Small molecule Oral
Subject VX-993 Unknown Oral

Indications